BioCorRx Inc. BICX
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BioCorRx Inc. is a biotechnology and healthcare solutions company focused on the treatment of substance use disorders, with an emphasis on alcohol and opioid addiction. The company operates in the addiction recovery and behavioral health sectors and is publicly traded on the OTC market under the ticker BICX. Its primary business activities include the development and commercialization of addiction treatment programs and pharmaceutical therapies designed to support long-term recovery and relapse prevention.
The company’s core business lines include the BioCorRx Recovery Program and the development of sustained-release therapeutic candidates through its subsidiary BioCorRx Pharmaceuticals Inc. The recovery program combines behavioral counseling, peer support, and physician-supervised treatment protocols, historically incorporating naltrexone-based approaches for alcohol and opioid dependence. BioCorRx has evolved from an addiction treatment marketing and referral business into a development-stage biotechnology company pursuing FDA-regulated therapies for substance use disorders. Public disclosures indicate the company’s strategic positioning centers on addressing unmet needs in addiction treatment through integrated behavioral and pharmaceutical approaches.
Business Operations
BioCorRx conducts operations primarily through two areas: addiction recovery program services and pharmaceutical development activities. Its behavioral health operations historically generated revenue through licensing, program fees, and affiliated treatment provider relationships connected to the BioCorRx Recovery Program. The company’s pharmaceutical activities are conducted through BioCorRx Pharmaceuticals Inc., which focuses on sustained-release formulations intended to improve patient compliance in addiction treatment settings.
The company’s development-stage pharmaceutical assets include BICX104, a naltrexone implant candidate for opioid and alcohol use disorders, and other abuse-deterrent or sustained-delivery addiction therapies referenced in public filings and investor materials. BioCorRx has also disclosed research collaborations and manufacturing relationships supporting formulation development and clinical advancement efforts. Operations are primarily U.S.-based, though the company has previously explored international licensing and commercialization opportunities related to addiction treatment technologies and therapeutic platforms.
Strategic Position & Investments
BioCorRx’s strategic direction is centered on expanding its addiction treatment pipeline and advancing regulated pharmaceutical products targeting substance use disorders. The company has emphasized long-acting therapeutic delivery systems designed to improve treatment adherence and reduce relapse risk. Public filings and investor communications indicate that BioCorRx has pursued grant-supported research initiatives and external funding opportunities to support clinical development activities.
A significant strategic asset is BioCorRx Pharmaceuticals Inc., which serves as the company’s principal pharmaceutical development subsidiary. BioCorRx has also explored partnerships involving contract research organizations, formulation specialists, and treatment providers to support commercialization and product development. Its focus on sustained-release addiction therapeutics places the company within broader trends involving medication-assisted treatment, behavioral health integration, and relapse prevention technologies. Available public information indicates that several pipeline programs remain in development stages, and commercial outcomes remain dependent on regulatory progress and financing availability.
Geographic Footprint
BioCorRx is headquartered in California, United States, and its operations are concentrated primarily within the U.S. addiction treatment and pharmaceutical development markets. The company’s recovery program model has historically involved affiliated providers and treatment relationships across multiple U.S. regions, particularly in areas with demand for alcohol and opioid dependency treatment services.
While the company does not maintain a broad multinational operating footprint comparable to large pharmaceutical firms, public disclosures indicate interest in international licensing opportunities and potential overseas commercialization arrangements for addiction treatment technologies. Its operational influence remains primarily domestic, with development and regulatory activities focused on the U.S. healthcare and biotechnology environment.
Leadership & Governance
BioCorRx’s leadership team has historically emphasized integrated addiction treatment solutions combining behavioral support with pharmaceutical innovation. Corporate strategy has focused on expanding treatment accessibility, developing sustained-release therapies, and advancing clinical-stage addiction treatment assets through partnerships and research initiatives.
Key executives and leadership figures identified in recent public filings include:
- Lourdes Felix – Chief Executive Officer
- Brady Granier – Chief Financial Officer
- Jeffrey Morris – Director
- Neil Muller – Director
Public company disclosures indicate leadership has prioritized capital formation, pharmaceutical pipeline advancement, and strategic collaborations within the addiction treatment and behavioral health sectors. Certain leadership roles and board compositions have changed periodically over time based on SEC filings and corporate governance updates.